Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million. TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to tre...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.